Overview

Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:
0

Participant gender:
All

Summary

1. In order to compare the benefit, side effects, and patient preference of Ropinirole prolonged release when used in once-daily or twice-daily dosing 2. In order to estimate the conversion rate of dopamine agonists into Ropinirole prolonged release

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Seoul National University Hospital

Treatments:

Ropinirole

Criteria

Inclusion Criteria:

1. Age: 30-80

2. Parkinson disease

3. On dopamine agonists (Ropinirole IR or Pramipexole IR) and are considering to change
into Ropinirole PR

4. On stable antiparkinsonian medication for at least 4 weeks

5. Who signed consent to the study

Exclusion Criteria:

1. Who are on less than 2 mg of Ropinirole IR or 0.375 mg of Pramipexole IR

2. Who have dementia, psychosis, major depression and other serious neurological or
medical problems

3. Who are allergic to the similar medications

4. Who has history of heavy metal poisoning

5. Who were on othe clinical trials of other medications within the last 4 weeks

6. Whoa re pregnant or lactating

7. Who are considered not eligible by the investigator